Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2022 Mar 11;10(3):e004044. doi: 10.1136/jitc-2021-004044

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© Author(s) (or their employer(s)) 2022. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.

This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See http://creativecommons.org/licenses/by-nc/4.0/.

PMC Copyright notice

Neoadjuvant in situ eCPMV immunotherapy induced a high neutrophilic infiltration in tumor samples and tumor emboli. Representative histopathology and immunostaining of tumor tissues from pretreatment/control and post-treatment samples. A strong neutrophilic infiltration is seen in post-treatment tumor tissues and emboli than in pretreatment tissues and tumor emboli as indicated by H&E and myeloperoxidase (MPO) expression. Higher Ki-67 proliferation index is observed in pretreatment tumor tissues and emboli than in post-treatment tumor tissues and emboli. There is no difference in cleaved caspase 3 (CC-3) immunolabeling between pretreatment tumor tissues and emboli than in post-treatment tumor tissues and emboli. eCPMV, empty cowpea mosaic virus.